logo
CEO Tom Gardner: "Look Where Others Aren't Looking" to Beat the Market Over the Next 3 to 5 Years

CEO Tom Gardner: "Look Where Others Aren't Looking" to Beat the Market Over the Next 3 to 5 Years

Globe and Mail10-07-2025
Key Points
The market may be entering a period of subpar performance for growth stocks.
Safer, income-oriented holdings may be on the verge of a market-beating phase.
This may be a good time to invest in companies that are more off the beaten path.
10 stocks we like better than Schwab U.S. Dividend Equity ETF ›
Want to beat the market? Most investors do. It's just easier said than done. Indeed, the risk and effort needed just to attempt to outperform the market can easily result in your underperforming it. That's why plenty of investors are content to merely match the stock market over the long term by buying and holding index funds.
Every now and then though, it makes sense to rethink the strategy of simply investing in the market as a whole or owning its obvious leading names. This may be one of these times.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
That was the key takeaway from a recent interview with The Motley Fool's co-founder and CEO Tom Gardner. "If you're looking for good returns over the next three to five years that beat the market," he said, "I think you need to look where others aren't looking right now." And he's right.
The question is, what does this mean in practical, actionable terms for the average investor? To answer that, it's helpful to first look three to five years back in time, and then, look back a bit further.
Not the long-term norm
As it is in life, the one constant in investing is change. The way things are now isn't the way they were in the past, nor is it the way they'll be in the foreseeable future. One only has to look back over the past few years to see it.
The so-called "Magnificent Seven" stocks (and their close peers) that have performed so brilliantly since 2020? They weren't exactly superstars in the years prior. Apple was hit-and-miss between 2012 and 2016, for instance, against a backdrop of slowing iPhone sales. Nvidia shares, which soared in the mid-2010s, were wrecked in 2018 when the crypto-mining craze cooled off. Meta Platforms (then Facebook) and Tesla performed equally inconsistently during the half-decade leading up to 2020, even if for different reasons.
But all of these powerhouses happened to benefit from a confluence of events: the explosion of artificial intelligence, rising interest in electric vehicles, and even demand driven by the advent of the COVID-19 pandemic. And due in part to their size, the raw strength of those few companies set the bullish tone for the rest of the market.
AAPL data by YCharts.
That upward push wasn't particularly healthy or sustainable, however. Indeed, it has arguably been unhealthy, by virtue of the lack of overall contribution to it by a broader group of stocks.
For perspective, the S&P 500 's seven biggest names today account for roughly one-third of its total value. Most of "the market's" bullishness in recent years was propelled by the aforementioned Nvidia and Meta, along with Microsoft and Amazon -- their far-above-average gains had an exaggerated impact on the S&P 500's performance specifically because they make up such large portions of the cap-weighted index.
To further clarify this, while some of these megacap stocks may now be back to record highs thanks to their big recovery from April's lows, fewer than a tenth of the S&P 500's constituents are actually in record-high territory. Nearly half of the index's tickers are still in the red for the year, in fact.
In short, the S&P 550 -- our most common proxy for the market -- has performed well for a while now thanks almost entirely to the gains of a handful of growth stocks in an environment that firmly favored them. That sort of cyclical dynamic can't be expected to last forever.
Here comes the cyclical shift
So now what?
Broadly speaking, some of the key conditions that tend to move growth stocks out of favor are already in place. Interest rates are higher and the economy has shifted to a slower-growing -- even if stable -- scenario. It's worth adding that the mania for artificial intelligence is finally settling down, with no obvious new trends on the horizon to stoke unchecked bullishness. Previous manias like electric vehicles and renewable energy aren't apt to be renewed either.
Ergo, without anything new or exciting enough to make investors ignore companies' lack of profits or outrageous valuations, Gardner believes "you need to look for dividend payers, more value-oriented investing," which rewards basic attributes like predictability and profitability. Something as simple as the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) or the Vanguard Value ETF (NYSEMKT: VTV) would fit the bill.
Picking stocks that are likely to be among the best performers for the next three to five years doesn't necessarily need to be a black-and-white, value-versus-growth affair, however.
"There are hundreds of good stocks to buy right now and own for the next five years, but they're probably not the most well-known [or] actively followed," said Gardner. "It's probably where people aren't looking. It's probably small caps. It's probably under-followed names."
Translation: Focus less on the now-struggling Magnificent Seven and FAANG components that have been considered must-have holdings for most of the past five years, and instead focus on the stocks of companies that are thriving even without the limelight.
Such businesses perhaps to consider now range from utility giant NextEra Energy to online bank SoFi Technologies to supermarket chain operator Kroger to beverage and snack powerhouse PepsiCo (which at its current share price is yielding 4.2%). These are relatively boring companies, but there's nothing boring about beating the market.
Take your time, but do embrace the change
So should this be an all-or-nothing strategic shift in your portfolio? No. Gardner is not suggesting any investor should simply upheave all of their familiar growth names and replace them with value stocks or dividend payers. Some growth stocks will perform well for the foreseeable future even if most large-cap growth stocks don't. Every prospective stock pick should still ultimately be made on a case-by-case basis based predominantly on the company's particular merits and prospects.
Investors should now be embracing a new philosophical mindset, though. Much of what has worked well in recent years -- like latching onto the market's biggest companies as they got bigger thanks to the advent of AI -- isn't apt to work as well going forward. Value stocks, dividend payers, and the more obscure stories may be better positioned to perform from here. Be sure to adjust your portfolio accordingly.
Should you invest $1,000 in Schwab U.S. Dividend Equity ETF right now?
Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,764!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $980,723!*
Now, it's worth noting Stock Advisor 's total average return is1,048% — a market-crushing outperformance compared to179%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Apple, Meta Platforms, Microsoft, NextEra Energy, Nvidia, Tesla, and Vanguard Index Funds-Vanguard Value ETF. The Motley Fool recommends Kroger and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Globe and Mail

timea minute ago

  • Globe and Mail

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889

New Thryv Workforce Center Manages Payroll for Small Businesses
New Thryv Workforce Center Manages Payroll for Small Businesses

Globe and Mail

timea minute ago

  • Globe and Mail

New Thryv Workforce Center Manages Payroll for Small Businesses

Managing in-house payroll processing and tax compliance can be a time-consuming challenge for small businesses. According to the National Small Business Association's 2025 survey, 50 percent of small businesses spend more than three hours per month administering payroll taxes. To mitigate concerns around time and accuracy, Thryv® (NASDAQ: THRY), the leading small business marketing and sales platform, has launched Thryv Workforce Center ™, a payroll solution designed for growing businesses. Powered by Gusto ™, the leading people management platform for small businesses, Thryv Workforce Center saves SMBs valuable time by managing payroll and automated tax calculations directly within their existing Thryv account. This press release features multimedia. View the full release here: This full-service solution does more than just calculate pay. It simplifies the entire payroll process, combining essential tools into one platform that manages a business' HR, taxes, and staff payments. It can also perform tasks like direct deposit and the creation of tax forms. 'Thryv is a trusted partner to over 100,000 small businesses and when we got growing requests to add payroll functionality to our platform, we listened,' said Rees Johnson, Thryv's Chief Product Officer. 'Most small businesses have to add separate payroll software, but now Thryv clients have the unique advantage of managing payroll within the same platform that they use daily for their business and marketing operations.' Noted Clayton Stokum, CEO of Alpha Behavior Strategies, 'Thryv has really helped me stay on top of the money coming in and made it easier to pay my employees as we continue to grow. It's given me clarity on where my money is going and that's been a game-changer.' Core Benefits of Thryv Workforce Center Centralized employee data: ensures all employee data and payroll information is stored in one secure, accessible location, reducing the risk of errors and saving time on administrative tasks. Payroll and automated tax filings: full-service payroll for W-2s and 1099s. Businesses can easily pay employees and contractors with automatic local, state and federal tax filings, helping to ensure tax compliance. Multiple payment options: employers can opt for either check or a two-day direct deposit via Plaid, Inc. Accessibility: employees can update direct deposit information and access pay stubs and tax forms at any time through the employee portal. Simple and transparent pricing: employers only pay active W-2 employees monthly, and contractors, only in the months they are paid. Unlimited payroll runs and filings are included. Flexibility: can be used by businesses looking to hire their first employee or those looking to switch from another system. 'We know small business owners everywhere want to save time and reduce errors with all-in-one solutions. With the launch of Thryv's Workforce Center, more small businesses in home services, healthcare, legal, and more now have a new option to manage their team and their business in one place," said Yi Liu, the General Manager of Gusto Embedded. "We're thrilled they partnered with Gusto Embedded to build a payroll product specifically designed for their customers within Thryv's platform.' ABOUT THRYV Thryv Holdings, Inc. (NASDAQ:THRY) is the provider of the leading sales and marketing platform designed to help small businesses attract new and repeat customers. Thryv software offers SMBs everything they need to manage day-to-day operations and grow efficiently. The platform's AI-supported marketing and business automations help business owners save time, compete, and win. More than 100K businesses globally use Thryv software to connect with customers and run and grow their business. For more information, visit

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

Globe and Mail

timea minute ago

  • Globe and Mail

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ('ADMA' or the 'Company'), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2025 financial results on August 6, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under 'Events & Webcasts' in the investor section of the Company's website at About ADMA Biologics, Inc. (ADMA) ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM ® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB ® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store